
A study sponsored by Cyberonics Inc., Houston, TX, shows that patients with treatment-resistant depression are very costly to the healthcare system due to extremely high use of both depression-related and general medical services. The study analyzed medical and prescription claims data from the 1995-1998 MEDSTAT MarketScan® Databases to evaluate healthcare utilization and costs of patients with treatment-resistant depression.
